Axoltis Pharma Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $20.8M

  • Investors
  • 12

Axoltis Pharma General Information

Description

Operator of a biotechnology company intended to treat patients suffering from severe neurological disorders. The company's drugs assist neural repair in treating patients with traumatic degenerative disorders of the central nervous system, faced with high unmet medical needs, enabling patients to get treatment for neurodegenerative diseases and improve functional recovery and quality of life.

Contact Information

Website
www.axoltis.com
Formerly Known As
Neuronax
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 15 - 17, Rue du Pré de la Reine
  • 63100 Clermont-Ferrand
  • France
+33 04
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 15 - 17, Rue du Pré de la Reine
  • 63100 Clermont-Ferrand
  • France
+33 04

Axoltis Pharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Axoltis Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A) 02-Dec-2025 $20.8M Completed Clinical Trials - Phase 2
4. Equity Crowdfunding 17-Nov-2025 Completed Clinical Trials - Phase 2
3. Later Stage VC 15-Jun-2016 Completed Clinical Trials - Phase 1
2. Equity Crowdfunding $51.9K $51.9K Completed Clinical Trials - Phase 1
1. Grant 01-Oct-2012 $772K Completed Clinical Trials - Phase 1
To view Axoltis Pharma’s complete valuation and funding history, request access »

Axoltis Pharma Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
To view Axoltis Pharma’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Axoltis Pharma Patents

  • 73

    Total Documents Applications and Grants

  • Total Patents Families

  • 32

    Granted

  • 19

    Pending

  • Expiring in next 12 mo

Axoltis Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022399936-A1 Sco-spondin-derived polypeptides for treating biological barriers dysfunction Pending 01-Dec-2021
CA-3239213-A1 Sco-spondin-derived polypeptides for treating biological barriers dysfunction Pending 01-Dec-2021
EP-4190347-A1 Sco-spondin-derived polypeptides for treating biological barriers dysfunction Inactive 01-Dec-2021
EP-4440600-A1 Sco-spondin-derived polypeptides for treating biological barriers dysfunction Pending 01-Dec-2021
US-20250152660-A1 Sco-spondin-derived polypeptides for treating biological barriers dysfunction Pending 01-Dec-2021 A61K38/12
To view Axoltis Pharma’s complete patent history, request access »

Axoltis Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Axoltis Pharma Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Auvergne-Rhône-Alpes Regional Future Industry Fund Venture Capital Minority
Cenitz Venture Capital Minority
Norfolk Capital Group Other Minority
ODDO BHF Group Asset Manager Minority
Simba Santé Other Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

Axoltis Pharma FAQs

  • When was Axoltis Pharma founded?

    Axoltis Pharma was founded in 2003.

  • Where is Axoltis Pharma headquartered?

    Axoltis Pharma is headquartered in Clermont-Ferrand, France.

  • What is the size of Axoltis Pharma?

    Axoltis Pharma has 15 total employees.

  • What industry is Axoltis Pharma in?

    Axoltis Pharma’s primary industry is Drug Discovery.

  • Is Axoltis Pharma a private or public company?

    Axoltis Pharma is a Private company.

  • What is Axoltis Pharma’s current revenue?

    The current revenue for Axoltis Pharma is .

  • How much funding has Axoltis Pharma raised over time?

    Axoltis Pharma has raised $25.5M.

  • Who are Axoltis Pharma’s investors?

    Auvergne-Rhône-Alpes Regional Future Industry Fund, Cenitz, Norfolk Capital Group, ODDO BHF Group, and Simba Santé are 5 of 12 investors who have invested in Axoltis Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process